Mibolerone (Oral)
Mibolerone (7alpha,17alpha-dimethyl-19-nortestosterone) is an extremely potent orally active 19-nor androgen originally licensed in veterinary medicine (Cheque Drops) to suppress estrus in dogs. In humans it is used non-medically in tiny sublingual/oral doses shortly before competition or heavy training for a short-lived surge in aggression; it is highly androgenic, progestogenic, hepatotoxic and dangerous at above micro-doses.
01 Overview
Mibolerone is a double-methylated (7-alpha and 17-alpha) nandrolone derivative, giving both oral activity and extreme receptor potency. Its veterinary use was estrus suppression in bitches; the human, non-medical use is a pre-workout or pre-fight 'aggression' aid taken in the low hundreds of micrograms.
Because of its potency and narrow margin, it is associated with rapid liver strain, severe suppression and pronounced mood/aggression effects. It is not suitable for sustained cycles and has no human therapeutic role.
02 Mechanism
Highly potent androgen-receptor agonist of the 19-nor class; 7-alpha and 17-alpha methyl groups block metabolism, giving oral potency and progestogenic activity.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Pre-event micro-dose | 100–300 mcg | Oral | Micrograms, not milligrams; taken shortly before activity. |
| Anecdotal | 300–500 mcg/day | Sublingual | Very short use only; risk rises sharply with dose/duration. |
Ester comparison
| Ester | Half-life | Injection freq. | Testosterone by mass |
|---|
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Acute aggression/drive surgeUsed for a pre-competition aggression boost. | marked, short-lived | Anecdotal | |
| Transient strength/intensityReported surge in training intensity. | acute | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Severe aggression / mood disturbanceUncontrolled aggression and irritability. | Severe | Common | Anecdotal | |
| Hepatotoxicity17-alpha-methyl group causes rapid hepatic strain. | Severe | Common with repeated use | Preclinical | |
| HPTA suppressionSevere suppression even at small doses. | Severe | Universal | Preclinical |